Which Is a Better Investment, Alkermes plc or Xencor, Inc. Stock?
Learn more about whether Alkermes plc or Xencor, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Commentary & Analysis
Why Alkermes plc’s (ALKS) Stock Is Down 5.18%
As of Wednesday, July 29, Alkermes plc’s ALKS share price has dipped by 5.18%, which has investors questioning if this is right time to buy.Jenna Brashear
What You Need to Know About Alkermes plc's Q3 Earnings
Alkermes plc's fiscal Q3 earnings report was released on Tuesday, July 28. Let's dive in to see if (ALKS) missed or beat analyst's expectations.Tudor Pop
Is Alkermes plc (ALKS) Overvalued?
We dive into why Alkermes plc (ALKS) could be considered overvalued on 2026-07-24, based on AAII’s Value Score and Grade.Tudor Pop
Which Is a Better Investment, Alkermes plc or CareDx, Inc. Stock?
Learn more about whether Alkermes plc or CareDx, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Financial Summary
| Share Statistics | ALKS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8,056.0 | $286.3 | 74% |
|
| Shares Out (Mil) | 173.5 | 54.2 | 74% |
|
| Institutional Ownership | 98.5% | 92.8% | 79% |
|
| Float (Mil) | 155.2 | 39.7 | 70% |
|
| Beta | 0.29 | 0.94 | 17% |
|
| Avg Daily Volume (000s) | 1,297 | 534 | 75% |
|
| Price Change (52-week) |
66.5% | 58.7% | 84% |
|
| Growth | ALKS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.3% | 13.6% | 47% |
|
| Net Income (5yr) | 33.1% | (10.1%) | 87% |
|
| EPS (5yr) | 32.3% | 16.0% | 83 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 62.8% | (15.6%) | 96% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | $0.247 | $1.275 | $1.828 | |
| Month Ago EPS | $0.415 | $1.234 | $1.638 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 2 | 1 | |
| Three Months Ago EPS | $0.481 | $1.433 | $2.355 | |
| Year/Year Chg | 8,133% | (10.8%) | 70.9% | |
| Financials | ALKS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,668 | $37 | 58% |
|
| Net Income (TTM) (Mil) | $66 | ($43) | 57% |
|
| EPS (TTM) | $0.399 | ($1.400) | 51% |
|
| Operating Cash Flow (TTM) (Mil) | $251 | ($31) | 62% |
|
| Net Cash Flow (TTM) (Mil) | ($10) | $2 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $1,539 | $4 | 71% |
|
| Enterprise Value (Q1) (Mil) | $9,388 | $160 | 73% |
|
| Valuation | ALKS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.45 | 2.77 | 75% |
|
| P/E | 123.8 | 19.1 | 95% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 3.8 | 1.0 | 83% |
|
| Ratios | ALKS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 87.2% | 64.2% | 92% |
|
| Net Margin | 4.0% | (75.9%) | 45% |
|
| ROA | 2.0% | (47.3%) | 56% |
|
| ROE | 3.9% | (55.0%) | 42% |
|
| Liabilities to Assets | 58.8% | 29.6% | 52% |
|
| F-Score | 4 | 2 | 34% |
|
Alkermes plc did not pass any screens on 8/20/2026.
